绥美凯中国上市了吗？

Is it listed in China? Suimeike is a new drug used to treat AIDS. In January 2018, GlaxoSmithKline China announced that it would be officially launched in China. It is used to treat adults and adolescents over 12 years old infected with the human immunodeficiency virus (HIV) weighing at least 40kg.

Suimeike was approved for marketing in the United States in 2014. It is currently the only three-in-one compound drug containing dolutegravir (DTG). It integrates treatment drugs for different stages of viral infection into the same tablet. Patients only need to take one drug to achieve the effect of combined medication. Moreover, oral administration greatly improves patients' medication compliance and improves their quality of life.

In 1987, the first anti-HIV agent zidovudine (AZT) came out, which began to bring hope to HIV patients. With the continuous advancement of medical technology, more and more new drugs are on the market, providing patients with more choices. Integrate DTG (dolutegravir) was launched in China in 2016, and its effect is remarkable. Now, Suimeike uses DTG, an integrase inhibitor, as the core drug, and combines it with the treatment plan of two backbone drugs, lamivudine and abacavir, and makes it into a single-tablet treatment for promotion, which makes the core drug make great progress in HAART treatment. It reduces the patient's medication burden, has few side effects, and is less likely to develop drug resistance. It is trusted by more and more HIV patients. In many authoritative institutions in Europe and the United States, Suimeikan has also been recommended as the first-line treatment of choice for patients with newly diagnosed HIV infection.

It is already on the market in my country and can be purchased by patients in hospitals with prescriptions issued by doctors. It should be noted that patients who are known to have hypersensitivity reactions to dolutegravir, abacavir, lamivudine or any excipients are prohibited from using Suimeikai. Patients with special circumstances need to take the medicine under the guidance of a doctor. If you have other questions, you can also consult a medical companion to understand the specific situation.